Research programme: platelet-derived growth factor receptor antagonists - Pulmokine

Drug Profile

Research programme: platelet-derived growth factor receptor antagonists - Pulmokine

Alternative Names: PDGF receptor kinase inhibitors - Pulmokine

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator YM BioSciences
  • Developer Pulmokine
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (Inhalation)
  • 27 Mar 2014 Pulmokine receives Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from National Heart, Lung and Blood Institute in the USA for inhaled PDGFR antagonists development in Pulmonary arterial hypertension
  • 14 Jan 2014 Pulmokine receives phase II SBIR grant from National Institutes of Health USA for PDGFR antagonist development in Pulmonary arterial hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top